Have a personal or library account? Click to login
Fetal Growth Restriction and Placental Markers: A Retrospective Study of First-Trimester Predictors Cover

Fetal Growth Restriction and Placental Markers: A Retrospective Study of First-Trimester Predictors

By: Z. Kirovakov and  A. Dushepeev  
Open Access
|Mar 2026

References

  1. Springer S, Worda K, Franz M, et al. Fetal growth restriction is associated with pregnancy associated plasma protein A and uterine artery Doppler in first trimester. J. Clin. Med., 2023, 12, 2502. https://doi.org/10.3390/jcm12072502
  2. Poon LC, Shennan A, Hyett JA, et al. The FIGO initiative on pre-eclampsia: a pragmatic guide for first-trimester screening and prevention. Int. J. Gynaecol. Obstet., 2019, 145, 1–33. https://doi.org/10.1002/ijgo.12802
  3. Karagiannis G, Akolekar R, Sarquis R, et al. Prediction of small-for-gestational-age neonates from biophysical and bio-chemical markers at 11–13 weeks. Fetal Diagn. Ther., 2011, 29, 148–154. https://doi.org/10.1159/000321694
  4. Velauthar L, Plana MN, Kalidindi M, et al. First-trimester uterine artery Doppler and adverse pregnancy outcome: a meta-analysis. Ultrasound Obstet. Gynecol., 2014, 43, 500–514. https://doi.org/10.1002/uog.13187
  5. Pilalis A, Souka AP, Antsaklis P, et al. Screening for pre-eclampsia and fetal growth restriction by uterine artery Doppler and PAPP-A at 11–14 weeks. Ultrasound Obstet. Gynecol., 2007, 29, 135–140. https://doi.org/10.1002/uog.3905
  6. He B, Hu C, Zhou Y. First-trimester screening for fetal growth restriction using uterine artery Doppler and serum PAPP-A levels. J. Matern. Fetal Neonatal Med., 2021, 34, 3857–3861. https://doi.org/10.1080/14767058.2019.1701646
  7. Morris RK, Bilagi A, Devani P, Kilby MD. Association of first-trimester PAPP-A levels with SGA and adverse pregnancy outcomes. Prenat Diagn, 2017; 37, 253–265. https://doi.org/10.1002/pd.5001
  8. Roberge S, Nicolaides KH, Demers S, Hyett J, Chaillet N, Bujold E. The role of aspirin dose on the prevention of pre-eclampsia and fetal growth restriction. Am. J. Obstet. Gynecol., 2017, 216, 110–120.e6. https://doi.org/10.1016/j.ajog.2016.09.076
  9. Lees CC, Stampalija T, Baschat AA, et al. The diagnosis and management of suspected fetal growth restriction: an evidence-based approach. Am. J. Obstet. Gynecol., 2022, 226, 366–378. https://doi.org/10.1016/j.ajog.2021.07.010
  10. Gaccioli F, Sovio U, Charnock-Jones DS, Smith GCS. Screening for fetal growth restriction using fetal biometry and maternal biomarkers. Am. J. Obstet. Gynecol., 2018, 218, S725–S737. https://doi.org/10.1016/j.ajog.2017.12.004
  11. Papageorghiou AT, Ohuma EO, Altman DG, et al. International standards for fetal growth: the INTERGROWTH-21st Project. Lancet, 2014, 384, 869–879. https://doi.org/10.1016/S0140-6736(14)61490-2
  12. Akolekar R, Syngelaki A, Sarquis R, et al. Prediction of early, intermediate, and late pre-eclampsia from maternal factors, biophysical and biochemical markers. Prenat. Diagn., 2011, 31, 66–74. https://doi.org/10.1002/pd.2637
  13. Gómez O, Figueras F, et al. Reference ranges for uterine artery PI from 11 to 41 weeks of gestation. Ultrasound Obstet. Gynecol., 2008, 32, 128-132. https://doi.org/10.1002/uog.5299
  14. Smith GCS, Stenhouse EJ, Crossley JA, et al. Early pregnancy PAPP-A and adverse outcomes. J. Clin. Endocrinol. Metab., 2002, 87, 1762–1767. https://doi.org/10.1210/jcem.87.4.8430
  15. D’Antonio F, Khalil A, Papageorghiou A, et al. Maternal serum PAPP-A and obstetric complications. Prenat. Diagn., 2013, 33, 839–847. https://doi.org/10.1002/pd.4141
  16. Figueras F, Gratacós E. Update on the diagnosis and classification of FGR. Am. J. Obstet. Gynecol., 2015, 213, S10–S17. https://doi.org/10.1016/j.ajog.2015.07.047
  17. Melamed N, Baschat A, Yinon Y, et al. FIGO best practice advice on FGR. Int. J. Gynecol. Obstet., 2021, 152, 3–57. https://doi.org/10.1002/ijgo.13522
  18. Petkova K, Ivanova D, Marinov M. Association between low PAPP-A and fetal outcomes in Bulgarian cohort. J. Matern. Fetal Neonatal Med., 2021, 34(24), 4087–4092. https://doi.org/10.1080/14767058.2020.1815647
  19. Livrinova V, Samardziski I, et al. Low first-trimester PAPP-A as a predictor of adverse outcomes. Open Access Maced. J. Med. Sci., 2018, 6(6), 1036–1040. https://doi.org/10.3889/oamjms.2018.211
  20. Krawczyk M. Impact of first trimester PAPP-A on infant birth weight. Ginekol. Pol., 2022, 93(1), 20–24. https://doi.org/10.5603/GP.a2022.0005
  21. Rizzo G, Capponi A, et al. First-trimester placental volume and vascularization in low PAPP-A pregnancies. J. Ultra-sound Med., 2009, 28, 1615–1622. https://doi.org/10.7863/jum.2009.28.12.1615
  22. Nicolaides KH. Screening for fetal aneuploidies at 11 to 13 weeks. Prenat. Diagn., 2011, 31, 7–15. https://doi.org/10.1002/pd.2637
  23. Tan MY, Syngelaki A, Poon LC, et al. Screening for preeclampsia and SGA: impact of aspirin. Ultrasound Obstet. Gynecol., 2018, 51, 743–750. https://doi.org/10.1002/uog.19055
  24. Sovio U, Smith GCS. Screening for fetal growth restriction with routine third trimester biometry. BMJ, 2020, 369, m1831. https://doi.org/10.1136/bmj.m1831
  25. Daskalakis G, Pilalis A, et al. Uterine artery Doppler and PAPP-A in first trimester screening for preeclampsia and IUGR. Arch. Gynecol. Obstet., 2012, 286, 153-160. https://doi.org/10.1007/s00404-012-2255-3.
  26. Sharma R, Saini D. Uterine artery Doppler and PAPP-A in prediction of preeclampsia and FGR. Int. J. Reprod. Contra-cept. Obstet. Gynecol., 2021, 10(4), 1453–1458. https://doi.org/10.18203/2320-1770.ijrcog20211111
  27. Kagan KO, Wright D, et al. Combined first trimester screening for preeclampsia. Ultrasound Obstet. Gynecol., 2008, 31, 617–622. https://doi.org/10.1002/uog.5332
  28. Sotiriadis A, Figueras F, et al. First and second trimester prediction of SGA and FGR. Ultrasound Obstet. Gynecol., 2018, 53, 55–61. https://doi.org/10.1002/uog.18950
  29. Lesmes C, Gallo DM, et al. Prediction of SGA by serum bio-chemical markers. Ultrasound Obstet. Gynecol., 2015, 46, 341–349. https://doi.org/10.1002/uog.14818
  30. Peixoto AB, et al. Reference ranges for uterine artery Doppler PI at mid trimester. J. Turk. Gynecol. Assoc., 2016, 17, 16–20. https://doi.org/10.4274/jtgga.2015.0180
  31. Georgieva D, Dimitrova N, Milcheva L, et al. Relationship between thyroid dysfunction and pregnancy complications: a retrospective study. Biomed. J. Sci. Tech. Res., 2023, 52(5), 8191–8196. https://doi.org/10.26717/BJSTR.2023.52.008191
  32. Andreeva E, Ivanov S, Kostadinova K, Petkova R. First-trimester maternal serum PAPP-A and β-hCG levels and their association with adverse pregnancy outcomes. Medicina, 2020, 56(12), 909. https://doi.org/10.3390/medicina60121909
  33. Gajjar P, Shah D. Association of uterine artery Doppler with adverse pregnancy outcomes. IOSR J. Dent. Med. Sci., 2021, 21(8), 61–72. https://doi.org/10.9790/0853-2108086172
  34. Chawla S, Puri M. First-trimester uterine artery Doppler and maternal serum PAPP-A and β-hCG in predicting preeclampsia and fetal growth restriction. OBM Genet., 2019, 3(4), Article 148. https://doi.org/10.15344/2455-2364/2019/148
  35. Gómez O, Figueras F, Fernández S, et al. Reference ranges for uterine artery mean pulsatility index at 11-41 weeks of gestation. Ultrasound Obstet. Gynecol., 2008, 32(2), 128-132. https://doi.org/10.1002/uog.20265
  36. Nikolova R, Tsvetkova M. Maternal serum biomarkers in early pregnancy as predictors of fetal growth restriction. Folia Med. (Plovdiv), 2023, 65(3), Article e86087. https://doi.org/10.3897/folmed.65.e86087
  37. Tzanaki I, Makrigiannakis A, Lymperopoulou C, et al. Pregnancy-associated plasma protein A (PAPP-A) as a first trimester serum biomarker for preeclampsia screening: a systematic review and meta-analysis. J. Matern. Fetal Neonatal Med., 2025, 38(1), Article 2448502. https://doi.org/10.1080/14767058.2024.2448502
  38. Masihi S, Amirgholami B, Nourian B, et al. Association of first-trimester low PAPP-A levels (< 0.2 MoM) with maternal and fetal outcomes. Eur. J. Med. Health Sci., 2025, 7(1). https://doi.org/10.24018/ejmed.2025.7.1.2233
DOI: https://doi.org/10.2478/amb-2026-0043 | Journal eISSN: 2719-5384 | Journal ISSN: 0324-1750
Language: English
Page range: 49 - 54
Submitted on: Aug 20, 2025
|
Accepted on: Sep 10, 2025
|
Published on: Mar 17, 2026
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2026 Z. Kirovakov, A. Dushepeev, published by Medical University - Sofia
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.